BACKGROUND: The long-term effects of smoking and smoking cessation on markers of cardiovascular disease (CVD) prognosis obtained during treadmill stress testing (TST) are unknown. The purpose of this study was to evaluate the long-term effects of smoking cessation and continued smoking on TST parameters that predict CVD risk. METHODS: In a prospective, double-blind, randomized, placebo-controlled trial of 5 smoking cessation pharmacotherapies, symptom-limited TST was performed to determine peak METs, rate-pressure product (RPP), heart rate (HR) increase, HR reserve, and 60-second HR recovery, before and 3 years after the target smoking cessation date. Relationships between TST parameters and treatments among successful abstainers and continuing smokers were evaluated using multivariable analyses. RESULTS: At baseline, the 600 current smokers (61% women) had a mean age of 43.4 (SD 11.5) years and smoked 20.7 (8.4) cigarettes per day. Their exercise capacity was 8.7 (2.3) METs, HR reserve was 86.6 (9.6)%, HR increase was 81.1 (20.9) beats/min, and HR recovery was 22.3 (11.3) beats. Cigarettes per day and pack-years were independently and inversely associated with baseline peak METs (P < .001), RPP (P < .01, pack-years only), HR increase (P < .05), and HR reserve (P < .01). After 3 years, 168 (28%) had quit smoking. Abstainers had greater improvements than continuing smokers (all P < .001) in RPP (2,055 mm Hg beats/min), HR increase (5.9 beats/min), and HR reserve (3.7%), even after statistical adjustment (all P < .001). CONCLUSIONS: Smokers with a higher smoking burden have lower exercise capacity, lower HR reserve, and a blunted exercise HR response. After 3 years, TST improvements suggestive of improved CVD prognosis were observed among successful abstainers.
RCT Entities:
BACKGROUND: The long-term effects of smoking and smoking cessation on markers of cardiovascular disease (CVD) prognosis obtained during treadmill stress testing (TST) are unknown. The purpose of this study was to evaluate the long-term effects of smoking cessation and continued smoking on TST parameters that predict CVD risk. METHODS: In a prospective, double-blind, randomized, placebo-controlled trial of 5 smoking cessation pharmacotherapies, symptom-limited TST was performed to determine peak METs, rate-pressure product (RPP), heart rate (HR) increase, HR reserve, and 60-second HR recovery, before and 3 years after the target smoking cessation date. Relationships between TST parameters and treatments among successful abstainers and continuing smokers were evaluated using multivariable analyses. RESULTS: At baseline, the 600 current smokers (61% women) had a mean age of 43.4 (SD 11.5) years and smoked 20.7 (8.4) cigarettes per day. Their exercise capacity was 8.7 (2.3) METs, HR reserve was 86.6 (9.6)%, HR increase was 81.1 (20.9) beats/min, and HR recovery was 22.3 (11.3) beats. Cigarettes per day and pack-years were independently and inversely associated with baseline peak METs (P < .001), RPP (P < .01, pack-years only), HR increase (P < .05), and HR reserve (P < .01). After 3 years, 168 (28%) had quit smoking. Abstainers had greater improvements than continuing smokers (all P < .001) in RPP (2,055 mm Hg beats/min), HR increase (5.9 beats/min), and HR reserve (3.7%), even after statistical adjustment (all P < .001). CONCLUSIONS: Smokers with a higher smoking burden have lower exercise capacity, lower HR reserve, and a blunted exercise HR response. After 3 years, TST improvements suggestive of improved CVD prognosis were observed among successful abstainers.
Authors: Kai P Savonen; Timo A Lakka; Jari A Laukkanen; Pirjo M Halonen; Tuomas H Rauramaa; Jukka T Salonen; Rainer Rauramaa Journal: Eur Heart J Date: 2006-01-06 Impact factor: 29.983
Authors: Douglas E Jorenby; J Taylor Hays; Nancy A Rigotti; Salomon Azoulay; Eric J Watsky; Kathryn E Williams; Clare B Billing; Jason Gong; Karen R Reeves Journal: JAMA Date: 2006-07-05 Impact factor: 56.272
Authors: Martha Gulati; Leslee J Shaw; Ronald A Thisted; Henry R Black; C Noel Bairey Merz; Morton F Arnsdorf Journal: Circulation Date: 2010-06-28 Impact factor: 29.690
Authors: Mamdouh M Shubair; Jennifer Kodis; Robert S McKelvie; Heather M Arthur; Arya M Sharma Journal: J Cardiopulm Rehabil Date: 2004 Nov-Dec Impact factor: 2.081
Authors: Megan E Piper; Stevens S Smith; Tanya R Schlam; Michael C Fiore; Douglas E Jorenby; David Fraser; Timothy B Baker Journal: Arch Gen Psychiatry Date: 2009-11
Authors: Claire M Bernaards; Jos W R Twisk; Willem Van Mechelen; Jan Snel; Han C G Kemper Journal: Med Sci Sports Exerc Date: 2003-05 Impact factor: 5.411
Authors: Erika Litvin Bloom; Haruka Minami; Richard A Brown; David R Strong; Deborah Riebe; Ana M Abrantes Journal: Psychol Health Med Date: 2017-01-19 Impact factor: 2.423
Authors: Diann E Gaalema; Patrick D Savage; Jason L Rengo; Alex Y Cutler; Rebecca J Elliott; Jeffrey S Priest; Stephen T Higgins; Philip A Ades Journal: J Cardiopulm Rehabil Prev Date: 2017-03 Impact factor: 2.081
Authors: Bethany C Bray; Rachel A Smith; Megan E Piper; Linda J Roberts; Timothy B Baker Journal: Nicotine Tob Res Date: 2016-07-13 Impact factor: 4.244
Authors: Timothy B Baker; Megan E Piper; James H Stein; Stevens S Smith; Daniel M Bolt; David L Fraser; Michael C Fiore Journal: JAMA Date: 2016-01-26 Impact factor: 56.272
Authors: Christine M Hoehner; Peg Allen; Carolyn E Barlow; Christine M Marx; Ross C Brownson; Mario Schootman Journal: Am J Epidemiol Date: 2013-08-13 Impact factor: 4.897
Authors: Adam D Gepner; Megan E Piper; Miguel A Leal; Asha Asthana; Michael C Fiore; Timothy B Baker; James H Stein Journal: PLoS One Date: 2013-04-23 Impact factor: 3.240
Authors: Hypatia A Bolívar; Rebecca J Elliott; William Middleton; Jin H Yoon; Chizimuzo T C Okoli; Ilana Haliwa; Charles C Miller; Philip A Ades; Diann E Gaalema Journal: J Cardiopulm Rehabil Prev Date: 2021-01-01 Impact factor: 3.646